THÔNG TIN TÀI LIỆU
Thông tin cơ bản
Định dạng | |
---|---|
Số trang | 164 |
Dung lượng | 8,3 MB |
Nội dung
Ngày đăng: 19/02/2014, 23:20
Nguồn tham khảo
Tài liệu tham khảo | Loại | Chi tiết |
---|---|---|
[1] Stuart S, MacIntyre K, Hole DJ, et al.: More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3(3): 315-322) [2] Grigioni F, Potena L, Galiè N, et al.: Prognostic implications of serial assessments ofpulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant.2006; 25: 1241-1246 | Khác | |
[3] Evgenov OV, Pacher P, Schmidt PM, et al.: NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat.Rev.Drug Discov.2006.Sep.;5(9.):755.-68. 2006, 5:755-768 | Khác | |
[4] Schermuly RT, Stasch JP, Pullamsetti SS, et al.: Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008; 32: 881-891 | Khác | |
[5] •• Stasch JP, Hobbs AJ: NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2009; (191): 277-308.This is an excellent overview of background of effects of NO-independent sGC stimulators | Khác | |
[6] Ghofrani HA, Hoeper MM, Hoeffken G, et al.: Riociguat Dose Titration in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or Pulmonary Arterial Hypertension (PAH). Conference abstract. 2009 American Thoracic Society International Conference, San Diego, USA, 16-20 May 2009 | Khác | |
[7] Mitrovic V, Swidnicki B, Ghofrani A, et al.: Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. Conference abstract. 4th International Conference on cGMP, Regensburg, Germany, 19-21 Jun 2009 | Khác | |
[8] Feil R, Kemp-Harper B: cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep.2006.Feb.;7.(2):149.- 53. 2006, 7:149-153 | Khác | |
[9] Lucas KA, Pitari GM, Kazerounian S, et al.: Guanylyl cyclases and signaling by cyclic GMP. Pharmacol.Rev.2000.Sep.;52.(3):375.-414. 2000, 52:375-414 | Khác | |
[10] •• Mitrovic V, Hernandez AF, Meyer M, et al.: Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail.Rev.2009.Dec.;14(4):309.-19. 2009, 14:309-319.This is a first-time overview of effects of pGC and sGC modulators in patients with heart failure. Natriuretic peptides (nesiritide and ularitide) lead to an increase of cGMP through stimulation of pGC; however. sGC stimulators and activators lead to an increase of intracellular cGMP through modulation of soluble guanylate cyclase | Khác | |
[11] Joseph L, Jr. Izzo, American Council on High Blood Pressure, and Henry R.Black: Hypertension Primer: The Essentials of High Blood Pressure 2003:Chapter A3, 8-13 [12] Burnett JC Jr.: Novel therapeutic directions for the natriuretic peptides in cardiovasculardiseases: what's on the horizon. J.Cardiol.2006.Nov.;48.(5):235.-41. 2006, 48:235-241 [13] Lee CY, Burnett, JC Jr.: Natriuretic peptides and therapeutic applications. HeartFail.Rev.2007.Jun.;12.(2):131.-42. 2007, 12:131-142 | Khác | |
[14] Clerico A, Iervasi G, Pilo A.: Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. Curr.Drug Metab.2000.Jul.;1(1):85.-105. 2000, 1:85-105 | Khác | |
[15] Volpe M, Tritto C, De Luca N, et al.: Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure.J.Clin.Invest. 1991, 88:1481-1489 | Khác | |
[16] • Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev.2007.Jan.;87.(1):315.-424. 2007, 87:315-424This paper describes the role of oxidative stress in cardiovascular disease | Khác | |
[17] Atlas SA, Maack T: Effects of atrial natriuretic factor on the kidney and the renin- angiotensin-aldosterone system. Endocrinol.Metab Clin.North Am. 1987, 16:107-143 [18] van der Zander K, Houben AJ, Hofstra L, et al.: Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo- controlled crossover study. Am.J.Physiol Heart Circ.Physiol.2003.Sep.;285.(3):H1206.-12.Epub.2003.May.8. 2003, 285:H1206-H1212 | Khác | |
[19] Mills RM, LeJemtel TH, Horton DP, et al.: Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group.J.Am.Coll.Cardiol. 1999, 34:155-162 | Khác | |
[20] Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.Circulation.2005.Mar.29.;111.(12.):1487.-91.Epub.2005.Mar.21. 2005, 111:1487-1491 [21] Luss H, Mitrovic V, Seferovic PM, Simeunovic D, et al. Renal effects of ularitide in | Khác | |
[22] Mitrovic V, Seferovic PM, Simeunovic D, et al.: Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur.Heart J.2006.Dec.;27.(23):2823.- 32.Epub.2006.Oct.30. 2006, 27:2823-2832 | Khác | |
[23] Su J, Scholz PM, Weiss HR: Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes.Exp.Biol.Med.(Maywood.).2005.Apr;230.(4):242.-50. 2005, 230:242-250 | Khác | |
[26] Packer M, Lee WH, Kessler PD, et al.: Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N.Engl.J.Med. 1987, 317:799-804 | Khác | |
[27] Foerster J, Harteneck C, Malkewitz J, et al.: A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits.Eur.J.Biochem. 1996, 240:380-386 | Khác |
TỪ KHÓA LIÊN QUAN
TÀI LIỆU CÙNG NGƯỜI DÙNG
TÀI LIỆU LIÊN QUAN